Table 1

Summary data presented in the papers reviewed

				Median (days)
Author, year, country	Cancer	Sample size	Age range (years)	TTD	PI	DI	Mean (days)	SD	Range (days)
Brasme JF, et al 201122, France	Medulloblastoma	166	<15	65					3–457
Klitbo DM, et al 201125, Denmark	Brain tumours	46	0–17	51	6	3			0–365
Shay V, et al 201129, Israel	Brain tumours	330	0–18				234		3–3283
Wilne SCJ, et al 201130, UK	Brain tumours	139	<17	100					0–2520
Hayashi N, et al 200931, Japan	Brain tumours	54	0–15	20.5
Kukal K, et al 200926, Switzerland	Brain tumours	315	0–16	60	14	14			0–3480
Reulecke BC, et al 200828, Germany	Brain tumours	245	<20	24			59		0–795
Mehta V, et al 200227, Canada	Brain tumours	104	≤17	91			222
Halperin EC, et al 200124, USA	Medulloblastoma	122	0–>17*				100	149.8
Edgeworth J, et al 199623, UK	Brain tumours	74	0–16				140	203.7	0–910
Bai S, et al 201132, China	Retinoblastoma	572	0–14	61			125	179.4	3–1094
Wallach M, et al 200635 Switzerland	Retinoblastoma	139	Children*				114
Rodrigues KES, et al 200434, Brazil	Retinoblastoma	327	≤12	91			176	200.6	3–1459
Wirix M, et al 200236, Belgium	Retinoblastoma	33	0–7				97		61–365
Goddard AG, et al 199933, UK	Retinoblastoma	100	<9*	56	18	14			7–672
Chotel F, et al 200837, UK	STS (synovial)	35	3–16				686†		2–2548
Ferrari A, et al 201038, Italy	STS	575	≤21	61					7–1824
Goyal S, et al 200439, UK	Bone tumours	115	4–22	116					30–1398
Yang JYK, et al 200940, Hong Kong	Osteosarcoma	51	3–20	61	30	21			4–361
Crawford JR, et al 200741, USA	CNSGCT	30	6–17				255
LaQuaglia MP, et al 199242, USA	Adenocarcinoma	29	≤21	61					12–547
Loh AHP, et al 201216, Singapore	Multiple	390	0–18	37	21	8			1–1982
Cecen E, et al 201111, Turkey	Multiple	329	0–19	53	3	28			0–2520
Stefan DC, et al 201120, South Africa	Multiple	194	0–15	34	5	20			2–1826
Haimi M, et al 201014, Israel	Multiple	315	0–20	49	7	28	110	188.9	0–1456
James BO, et al 200915, Nigeria	Multiple	64	1–14	92	14	62	169	196	15–1098
Dang-Tan T, et al 200812, Canada	Multiple	2896	0–19	30	9	8			13–69‡
Martin S, et al 200717, USA	Multiple	235	15–29				75	24.4
Thulesuis H, et al 200021, Sweden	Multiple	64	0–16	63§	35§	21§			1–1393§
Saha V, et al 199319, UK	Multiple	184	0–15	28¶
Pollock BH, et al 199218, USA	Multiple	2665	0–29				(50)**
Flores LE, et al 198613, USA	Multiple	79	<20				(77)††

*Age ranges are not clearly defined, however all refer to the study of children.
†Mean PI is reported as 301 days (0–1092) and mean DI as 350 days (0–2534).
‡The IQR is shown.
§These are the reported values for brain tumour patients; the paper also reports leukaemia TTD as 21 days, PI as 1 and DI as 0.
¶Median TTD 28 days (7–364 days) for 101 males and 28 days (7–504 days) for 83 females.
**This is a combined mean from the mean for each cancer group, included so the paper could be displayed in the review results.
††Combined mean of mean TTD in 79 brain tumour, 45 Wilms’ tumour and 123 leukaemia cases, included so the paper could be displayed in the review results.
CNSGCT, central nervous system germ cell tumours; DI, doctor interval; STS, soft tissue sarcoma; TTD, time to diagnosis; PI, patient interval.